Announcements
- Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
- Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
- Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
- Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
- Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
- Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
- Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
- Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
- Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
More ▼
Key statistics
On Thursday, Biora Therapeutics Inc (4ZU0:BER) closed at 0.57, 14.00% above the 52 week low of 0.50 set on May 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.585 |
---|---|
High | 0.585 |
Low | 0.57 |
Bid | 0.535 |
Offer | 0.61 |
Previous close | 0.585 |
Average volume | 1.12k |
---|---|
Shares outstanding | 35.88m |
Free float | 35.54m |
P/E (TTM) | -- |
Market cap | 22.50m USD |
EPS (TTM) | -7.13 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 19:08 BST.
More ▼